Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 514Radiotherapy 376Cyclophosphamide 364Carboplatin 356Capecitabine 342Oxaliplatin 334Paclitaxel 331Gemcitabine 320Docetaxel 315Fluorouracil 290Drug Therapy 273Bevacizumab 247apatinib 246camrelizumab 218Etoposide 200Irinotecan 183Doxorubicin 181Leucovorin 163Dexamethasone 160pembrolizumab 154sintilimab 143Neoadjuvant Therapy 143anlotinib 140Blood Specimen Collection 139Pemetrexed 138Cytarabine 138toripalimab 131Surgical Procedures, Operative 131Radiosurgery 127S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lysine × Clear all
NCT03478358 2022-08-31

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Peking Union Medical College Hospital

Phase 1 Unknown
60 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡